Ability to predict biochemical progression using gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei

Urology

Volumn 48, Issue 5, 1996, Pages 685-691

  Veltri, Robert W ^a   Miller, M Craig ^b   Partin, Alan W ^b   Coffey, Donald S ^b   Epstein, Jonathan I ^b  

^a UroSciences Group   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GROWTH; CANCER RECURRENCE; CELL NUCLEUS; COMPUTER ANALYSIS; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEUS; DIAGNOSIS, COMPUTER-ASSISTED; DISEASE PROGRESSION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0030297751     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00370-6     Document Type: Article

References (36)

1. 1. Wingo PA, Tong T, and Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45: 8-30, 1995.
2. 2. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tamaszewski JE, and Wein A: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 154: 131-138, 1995.
3. 3. Partin AW, and Oesterling JE: The clinical usefulness of prostate specific antigen: update 1994. J Urol 152: 1358-1368, 1993.
4. 4. Shevlin BE, Mittal BB, Brand WN, and Shetty RN: The role of adjuvant irradiation following primary prostatectomy, based on histopathologic extent of tumor. Int J Radiat Oncol Biol Phys 16: 1425-1430, 1989.
5. 5. Stein A, deKernion JB, and Dorey F: Prostatic-specific antigen related to clinical status 1 to 14 years after radical retropubic prostatectomy. Br J Urol 67: 626-631, 1991.
6. 6. Frazier A, Robertson JE, Humphrey PA, and Paulson DF: Is prostate-specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol, 149: 516-518, 1993.
7. 7. Epstein JI, Pizov G, Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71: 3582-3593, 1993.
8. 8. Epstein JI, Carmichael MJ, Pizov G, and Walsh PC: Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term follow up. J Urol 150: 135-141, 1993.
9. 9. Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, Brendler CB, Walsh PC, and Simons JW: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45: 831-838, 1995.
10. 10. McNeal JE, Villers AA, Redwine EA, Freiha FS, and Stamey TA: Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol 14: 240-247, 1990.
11. 11. McNeal JE: Cancer volume and site of origin of adenocarcinoma of the prostate: relationship to local and distant spread. Hum Pathol 23: 258-266, 1992.
12. 12. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 23: 273-279, 1992.
13. 13. Greene DR, Taylor SR, Wheeler TM, and Scardino PT: DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report. Cancer Res 51: 4084-4089, 1991.
14. 14. van den Ouden D, Tribukait B, Blom JHM, Fossa SD, Kurth KH, ten Kate FJW, Heiden T, Wang N, Schroder FH, and The European Organization for Research and Treatment of Cancer Genitourinary Group: Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients impact on time to progression. J Urol 150: 400-406, 1993.
15. 15. Babiarz J, Peters JM, Miles B, and Crissman JD: Comparison of DNA content in primary and lymph node metastases in prostate adenocarcinoma. Anal Quant Cytol Histol 15: 158-164, 1993.
16. 16. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, and Epstein JI: Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 153: 1015-1019, 1995.
17. 17. Veltri RW, Partin AW, Epstein JI, Marley GM, Miller MC, Singer DP, Patton KP, Criley SR, and Coffey DS: Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and Her-2-neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem Suppl 19: 249-258, 1994.
18. 18. Diamond DA, Berry SJ, Jewett HJ, Eggleston JC, and Coffey DS: A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness. J Urol 128: 729-734, 1982.
19. 19. Diamond DA, Berry SJ, Umbricht C, Jewett HJ, and Coffey DS: Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer. Prostate 3: 321-332, 1982.
20. 20. Mohler JL, Partin AW, Lohr WD, and Coffey DS: Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. I. Testing of a digitization system. J Urol 139: 1080-1084, 1988.
21. 21. Mohler JL, Partin AW, Epstein JI, Lohr WD, and Coffey DS: Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II. Standardization of methodology for histologic sections. J Urol 139: 1085-1090, 1988.
22. 22. Wang N, Stenkvist BG, and Tribukait B: Morphometry of nuclei of the normal and malignant prostate in relation to DNA ploidy. Analyt Quant Cytol Histol 14: 210-216, 1992.
23. 23. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, and Coffey DS: A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J Urol 142: 1254-1258, 1989.
24. 24. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, and Epstein JI: Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer 70: 161-168, 1992.
25. 25. Partin AW, Carter HB, Epstein JI, and Coffey DS: The biology of prostate cancer: new and future directions in predicting tumor behavior. Monogr Pathol 34: 198-218, 1992.
26. 26. Bacus JW, and Grace LJ: Optical microscope system for standardized cell measurements and analyses. Appl Opt 26: 3280-3293, 1987.
27. 27. Bacus SS, Bacus JW, Bacus JV, Chin DM, Ortiz R, Stern RK, and Morrow DW: Prostate adenocarcinoma: an image analysis technique for DNA ploidy determination. Lab Med 24: 225-231, 1993.
28. 28. Bacus JW, and Bacus JV: Quality control in image cytometry: DNA ploidy. J Cell Biochem Suppl 19: 153-164, 1994.
29. 29. Pressman NJ: Markovian analysis of cervical cell images. J Histochem Cytochem 24: 138-144, 1976.
30. 30. Dawson AE, Cibas ES, Bacus JW, and Weinberg DS: Chromatin texture measurement by Markovian analysis: use of nuclear models to define and select texture features. Anal Quant Cytol Histol 15: 227-235, 1993.
31. 31. Hosmer DW, and Lemeshow S: Applied Logistic Regression. New York, John Wiley & Sons, 1989.
32. 32. Vollmer RT: Multivariate statistical analysis for pathologists. Am J Clin Pathol 105: 115-126, 1996.
33. 33. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, and Walsh PC: The use of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114, 1993.
34. 34. Haykin, S: Neural Networks: A Comprehensive Foundation. New York, Macmillan, 1994.
35. 35. Bartels PH: Computer-generated diagnosis and image analysis: an overview. Cancer 69: 1636-1638, 1992.
36. 36. Wojno K, Schwab ED, Consolino CM, and Oesterling JE: Fractal analysis of the Gleason grading system (Abstract). Mod Pathol 9: 86a, 1996.